New study shows paclitaxel may benefit Alzheimer's and Parkinson's movement disorders
22 Dezember 2004 - 7:38PM
PR Newswire (US)
New study shows paclitaxel may benefit Alzheimer's and Parkinson's
movement disorders VANCOUVER, Dec. 22 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today
announced that a preclinical study published in today's early
edition of the Proceedings of the National Academy of Sciences
highlights the positive effects of PAXCEED(TM) on movement
disorders commonly seen in diseases known as taupathies, such as
Alzheimer's and Parkinson's. Results from the study reveal that
injected paclitaxel (PAXCEED(TM)) appear to restore nerve function
in an animal model. In the study, it was demonstrated that low
(10mg/m(2)) and medium (25mg/m(2)) doses of PAXCEED(TM) had two
major effects: 1) improving axonal transport and 2) increasing the
amounts of tubulin and microtubules, proteins and cell structures
vital for nerve structure and conduction. "We are excited as this
is the first experimental evidence to support the use of paclitaxel
as a novel intervention for the treatment of Alzheimer's and other
neurodegenerative diseases," said William Hunter, MD, CEO of
Angiotech. "We have long believed that a microtubule stabilizing
agent used systemically would hold great promise in these types of
diseases, and we look forward to advancing the results of these
studies into humans." Abnormal tau proteins are often seen as
mechanisms that can lead to brain degeneration in Alzheimer's
disease and other neurodegenerative disorders known as taupathies.
In all taupathies, there are neuropathologic aggregates of paired
helical filaments and/or straight filaments composed of aberrantly
phosphorylated tau proteins in central nervous system neurons or
glia. It has been shown that these abnormally filamentous proteins
cannot perform the important functions of binding and stabilizing
microtubules which often leads to a dramatic increase in
neurofibrillary tangles and neuropil threads seen in Alzheimer's.
Angiotech believes that systemic paclitaxel (PAXCEED(TM)), a
microtubule stabilizing agent, may ultimately show a therapeutic
benefit to patients with Alzheimer's disease and other taupathies
by offsetting the loss of normal tau function. Vancouver-based
Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company
focusing on drug-eluting medical devices and biomaterials, is
dedicated to enhancing the performance of medical devices and
biomaterials through the innovative uses of pharmacotherapeutics.
To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. CONTACTS: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors) (604) 221-7676 ext 6933
Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts) (604)
221-7676 ext 6996 Eric Starkman, Starkman & Associates (Media)
(212) 252-8545 ext 12 DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Todd Young, Angiotech Pharmaceuticals (Analysts &
Investors), (604) 221-7676 ext 6933; Rui Avelar, Angiotech
Pharmaceuticals, Inc. (Analysts), (604) 221-7676 ext 6996; Eric
Starkman, Starkman & Associates (Media), (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Angiotech Pharmaceuticals (MM) News-Artikel